Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties:: Synthesis, structure, electrochemistry, and cytotoxicity

被引：130

作者：

Auzias, Mathieu ^{[1
]}

Therrien, Bruno ^{[1
]}

Suess-Fink, Georg ^{[1
]}

Stepnicka, Petr ^{[2
]}

Ang, Wee Han ^{[3
]}

Dyson, Paul J. ^{[3
]}

机构：

[1] Univ Neuchatel, Inst Chim, CH-2009 Neuchatel, Switzerland

[2] Charles Univ Prague, Fac Sci, Dept Inorgan Chem, CZ-12840 Prague 2, Czech Republic

[3] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, CH-1015 Lausanne, Switzerland

来源：

INORGANIC CHEMISTRY | 2008年 / 47卷 / 02期

关键词：

D O I：

10.1021/ic7018742

中图分类号：

O61 [无机化学];

学科分类号：

070301 ; 081704 ;

摘要：

Organometallic ruthenium(II) complexes of general formula [RU(eta(6)-arene)Cl-2(NC5H4OOC-C5H4FeC5H5)], where arene = C6H6 (1), C6H5Me (2), p-(PrC6H4Me)-Pr-i (3), and C6Me6 (4), and of general formula [Ru(eta(6)-arene)Cl-2](2)(NC5H4OOC-C5H4FeC5H4-COOC5H4N), where arene = p-(PrC6H4Me)-Pr-i (5) and C6Me6 (6), have been synthesized and characterized, the molecular structures of these complexes being confirmed by single-crystal X-ray structure analysis of complex 4 as a representative example. The redox properties and in vitro anticancer activities of complexes 1-6 have been studied. All the compounds are moderately cytotoxic toward the A2780 and A2780cisR (cisplatin-resistant) human ovarian carcinoma cell lines. The diruthenium arene complexes 5 and 6 are about twice as active as their mononuclear analogues 3 and 4. Cyclic voltammetry revealed a good correlation of the Ru-II/Ru-III redox potentials of 1-4 and the number of alkyl substituents in the arene ligand.

引用

页码：578 / 583

页数：6

共 56 条

[31]

Messori L., 2000, Metal-Based Drugs, V7, P335, DOI 10.1155/MBD.2000.335

[32] Inhibition of cancer cell growth by ruthenium(II) arene complexes [J].

Morris, RE ;

Aird, RE ;

Murdoch, PD ;

Chen, HM ;

Cummings, J ;

Hughes, ND ;

Parsons, S ;

Parkin, A ;

Boyd, G ;

Jodrell, DI ;

Sadler, PJ .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (22) :3616-3621

[33] Selective estrogen receptor modulators in the ruthenocene series.: Synthesis and biological behavior [J].

Pigeon, P ;

Top, S ;

Vessières, A ;

Huché, M ;

Hillard, EA ;

Salomon, E ;

Jaouen, G .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (08) :2814-2821

[34]

POLECPAWLAK K, 2000, ELETROPHORESIS, V27, P1128

[35] Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy [J].

Pongratz, M ;

Schluga, P ;

Jakupec, MA ;

Arion, VB ;

Hartinger, CG ;

Allmaier, G ;

Keppler, BK .

JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY, 2004, 19 (01) :46-51

[36] ANTITUMOR EFFECTS OF BINUCLEAR FERROCENE DERIVATIVES [J].

POPOVA, LV ;

BABIN, VN ;

BELOUSOV, YA ;

NEKRASOV, YS ;

SNEGIREVA, AE ;

BORODINA, NP ;

SHAPOSHNIKOVA, GM ;

BYCHENKO, OB ;

RAEVSKII, PM ;

MOROZOVA, NB ;

ILYINA, AI ;

SHITKOV, KG .

APPLIED ORGANOMETALLIC CHEMISTRY, 1993, 7 (02) :85-94

[37] A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent [J].

Rademaker-Lakhai, JM ;

van den Bongard, D ;

Pluim, D ;

Beijnen, JH ;

Schellens, JHM .

CLINICAL CANCER RESEARCH, 2004, 10 (11) :3717-3727

[38] CISPLATIN - SYNTHESIS, ANTITUMOUR ACTIVITY AND MECHANISM OF ACTION [J].

REEDIJK, J ;

LOHMAN, PHM .

PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1985, 7 (05) :173-180

[39] Improved understanding in platinum antitumour chemistry [J].

Reedijk, J .

CHEMICAL COMMUNICATIONS, 1996, (07) :801-806

[40] PLATINUM COMPOUNDS - A NEW CLASS OF POTENT ANTITUMOUR AGENTS [J].

ROSENBERG, B ;

VANCAMP, L ;

TROSKO, JE ;

MANSOUR, VH .

NATURE, 1969, 222 (5191) :385-+

← 1 2 3 4 5 6 →